Skip to content
PeptideHormone

Pasireotide

A broader-spectrum somatostatin analog hitting more receptor subtypes.

Also known as Signifor.

AnalogEstablishedBased on SomatostatinCompare with SST Compare lineage

Deliberately less selective than its predecessors, on the logic that a broader grip on the receptor family answers what a narrow one cannot.

Identity

Class
Somatostatin analog (cyclic hexapeptide)
Source
Synthetic analog of somatostatin
Receptor
Somatostatin receptors (SSTR1, 2, 3, and 5)

Key properties

Evidence floorClinicalREF1CLIN1
Molecular weight
~1,047.2 Da
REF
Half-life (native)
~12 h
CLIN
Model dosing

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

Pasireotide binds a wider range of somatostatin receptor subtypes than octreotide — including SSTR1, 2, 3, and 5 — giving it a different activity profile, notably more SSTR5 engagement that underlies its use in conditions octreotide addresses less well.

Reference notes

  • Its broader SSTR-subtype coverage is the key distinction from octreotide and lanreotide.
  • Greater SSTR5 affinity drives a different clinical profile.
  • Illustrates how analog receptor-selectivity engineering changes effects.

Common questions

What is Pasireotide?
A broader-spectrum somatostatin analog hitting more receptor subtypes. Structurally it is Somatostatin analog (cyclic hexapeptide).
How does Pasireotide work?
Pasireotide binds a wider range of somatostatin receptor subtypes than octreotide — including SSTR1, 2, 3, and 5 — giving it a different activity profile, notably more SSTR5 engagement that underlies its use in conditions octreotide addresses less well.
How strong is the evidence for Pasireotide?
PeptideHormone grades Pasireotide at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of Pasireotide?
The reported circulating half-life of Pasireotide is ~12 h.
Is Pasireotide the same as Signifor?
Signifor is a brand name of Pasireotide — the same molecule in different approved presentations. This page is the molecule reference, not a prescribing guide.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

  1. 1.Diagnosis and Treatment of Pituitary Adenomas: A Review · JAMA, 2017 · PMID 28170483
  2. 2.Acromegaly · Nature reviews. Disease primers, 2019 · PMID 30899019

External references

Pasireotide in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.